Priestle J P, Fässler A, Rösel J, Tintelnot-Blomley M, Strop P, Grütter M G
Department of Core Drug Discovery Technologies, Pharma Research, Ciba-Geigy Ltd., Basel, Switzerland.
Structure. 1995 Apr 15;3(4):381-9. doi: 10.1016/s0969-2126(01)00169-1.
The human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS). Two subtypes of the virus, HIV-1 and HIV-2, have been characterized. The protease enzymes from these two subtypes, which are aspartic acid proteases and have been found to be essential for maturation of the infectious particle, share about 50% sequence identity. Differences in substrate and inhibitor binding between these enzymes have been previously reported.
We report the X-ray crystal structures of both HIV-1 and HIV-2 proteases each in complex with the pseudosymmetric inhibitor, CGP 53820, to 2.2 A and 2.3 A, respectively. In both structures, the entire enzyme and inhibitor could be located. The structures confirmed earlier modeling studies. Differences between the CGP 53820 inhibitory binding constants for the two enzymes could be correlated with structural differences.
Minor sequence changes in subsites at the active site can explain some of the observed differences in substrate and inhibitor binding between the two enzymes. The information gained from this investigation may help in the design of equipotent HIV-1/HIV-2 protease inhibitors.
人类免疫缺陷病毒(HIV)是获得性免疫缺陷综合征(AIDS)的病原体。该病毒已被鉴定出两种亚型,即HIV-1和HIV-2。这两种亚型的蛋白酶均为天冬氨酸蛋白酶,已发现其对感染性颗粒的成熟至关重要,二者的序列同一性约为50%。此前已有关于这两种酶在底物和抑制剂结合方面差异的报道。
我们报道了HIV-1和HIV-2蛋白酶分别与假对称抑制剂CGP 53820形成复合物的X射线晶体结构,分辨率分别为2.2 Å和2.3 Å。在这两种结构中,整个酶和抑制剂均可定位。这些结构证实了早期的建模研究。两种酶的CGP 53820抑制结合常数的差异与结构差异相关。
活性位点亚位点的微小序列变化可以解释两种酶在底物和抑制剂结合方面观察到的一些差异。从这项研究中获得的信息可能有助于设计等效的HIV-1/HIV-2蛋白酶抑制剂。